Our observation that the PDE3A2/SMAD4/HDAC-1 nanodomain also operates in human cardiac myocytes differentiated from 4 independent pluripotent stem cell lines indicates that this pathway may contribute to the negative long-term clinical outcome observed in patients with HF receiving PDE3 inhibitors. The gene discussed is HDAC1; the disease is hydrops fetalis.